On March 6, Tiankang Bio said on the investor interaction platform that the company currently has no plan to transfer its main business to Tiankang Pharmaceutical, nor does it have any plan to inject assets into Tiankang Pharmaceutical.

In December 2024, Tiankang Bio announced that its holding subsidiary Tiankang Pharmaceutical intends to apply for a public offering of shares to unspecified qualified investors and list on the Beijing Stock Exchange. Tiankang Bio believes that this move will help further enhance Tiankang Pharmaceutical's production capacity and R&D and innovation capabilities, promote business development, and improve its governance level and industry competitiveness. After the completion of this public offering, Tiankang Bio will still be the controlling shareholder of Tiankang Pharmaceutical, and both the company and Tiankang Pharmaceutical will be able to continue to maintain independence and sustainable operating capabilities.

Recently, an investor asked on the interactive platform whether Tiankang Pharmaceutical will transfer part of Tiankang Bio's main business after listing, and whether it will be injected with assets by Tiankang Bio. On March 6, Tiankang Bio responded that the company currently has no plan to transfer its main businesses such as feed, pig farming, and agricultural product processing to Tiankang Pharmaceutical, nor does it have any plans to inject assets into Tiankang Pharmaceutical. From the perspective of business positioning and actual operation, the business boundaries between Tiankang Bio and Tiankang Pharmaceutical are clear, and there is no "market confusion behavior" prohibited by Article 6 of the Anti-Unfair Competition Law.

Tiankang Bio pointed out that Tiankang Pharmaceutical focuses on the field of veterinary vaccines, while Tiankang Bio has comprehensive development in multiple fields such as feed, pig farming, slaughtering and processing, and meat product sales. There are significant differences in the customer groups, business channels, and market positioning of both parties. The public can clearly distinguish the business scope of the two. At the same time, in the long-term development process of Tiankang Bio, each business segment has established an independent and mature brand image and market awareness, which is independent of the brand of Tiankang Pharmaceutical and will not cause market confusion. In the future, the company will continue to improve its governance structure, strengthen information disclosure, ensure the compliance operation of each business segment, and maintain a good market order.

https://finance.eastmoney.com/a/202503073339608643.html